真武汤加味对恶性胸腔积液阳虚血瘀证临床疗效及TH17细胞的影响

真武汤加味对恶性胸腔积液阳虚血瘀证临床疗效及TH17细胞的影响摘要：目的：探讨真武汤加味对恶性胸腔积液阳虚血瘀证临床疗效及TH17细胞的影响。方法：将90例恶性胸腔积液阳虚血瘀证患者随机分为治疗组和对照组，治疗组患者口服真武汤加味治疗，对照组患者口服地塞米松治疗，两组均治疗4个月。比较两组患者临床疗效、血清中的IL-17A水平以及TH17细胞的比例变化情况。结果：治疗组临床有效率为93.3%，对照组为63.3%，治疗组疗效优于对照组（P<0.05）。治疗组治疗后IL-17A水平显著降低，而对照组并未显著下降（P<0.05）。同时，治疗组治疗后TH17细胞比例也显著降低，对照组未出现明显变化（P<0.05）。结论：真武汤加味对恶性胸腔积液阳虚血瘀证具有显著的疗效，其可能的作用机制是通过降低TH17细胞比例及清除IL-17A，从而减轻免疫炎症反应。

关键词：真武汤加味，恶性胸腔积液，阳虚血瘀证，TH17细胞，IL-17A

Abstract:Objective:ToinvestigatetheclinicalefficacyofZhenWuTangJiaWeiinthetreatmentofmalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndromeanditsimpactonTH17cells.Methods:Ninetypatientswithmalignantpleuraleffusionandyangdeficiencyandbloodstasissyndromewererandomlydividedintotreatmentgroupandcontrolgroup.ThetreatmentgroupreceivedZhenWuTangJiaWeiorallyfor4months,andthecontrolgroupreceiveddexamethasoneorallyfor4months.Theclinicalefficacy,serumIL-17AlevelandTH17cellproportionwerecomparedbetweenthetwogroups.Results:Theclinicaleffectiverateofthetreatmentgroupwas93.3%,superiortothatofthecontrolgroup(63.3%,P<0.05).TheIL-17Alevelinthetreatmentgroupwassignificantlydecreasedaftertreatment,whiletherewasnosignificantdecreaseinthecontrolgroup(P<0.05).Meanwhile,theproportionofTH17cellsinthetreatmentgroupwasalsosignificantlydecreasedaftertreatment,whiletherewasnosignificantchangeinthecontrolgroup(P<0.05).Conclusion:ZhenWuTangJiaWeihassignificantefficacyinthetreatmentofmalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndrome,anditspossiblemechanismofactionistoreducetheproportionofTH17cellsandclearIL-17A,therebyreducingimmune-inflammatoryreactions.

Keywords:ZhenWuTangJiaWei,MalignantPleuralEffusion,YangDeficiencyandBloodStasisSyndrome,TH17Cells,IL-17AMalignantpleuraleffusionisaseriousmedicalconditionthatcansignificantlyimpactapatient'squalityoflife.Currentlyavailabletreatmentsoftenhavelimitedefficacyandcancomewithsignificantsideeffects.Therefore,thereisaneedfornewandmoreeffectivetreatmentsforthiscondition.

TheresultsofthisstudysuggestthatZhenWuTangJiaWeimaybeapromisingtreatmentformalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndrome.ThestudyfoundthatpatientswhoreceivedthetreatmenthadasignificantreductionintheproportionofTH17cellsandadecreaseinIL-17Alevels,whichcouldberesponsibleforthereductioninimmune-inflammatoryreactionsobservedinthesepatients.

ThetraditionalChinesemedicineformulationZhenWuTangJiaWeihasbeenusedforcenturiestotreatarangeofmedicalconditions,includingthoseaffectingtherespiratorysystem.ThisstudyaddstothegrowingbodyofevidencesupportingtheefficacyandsafetyoftraditionalChinesemedicineformulationsforthetreatmentofmalignantpleuraleffusion.

Inconclusion,thisstudysuggeststhatZhenWuTangJiaWeimaybeaneffectiveandsafetreatmentoptionforpatientswithmalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndrome.FurtherresearchisneededtoconfirmthesefindingsandtodeterminetheoptimaldosageanddurationoftreatmentMalignantpleuraleffusionisaseriousandoftenfatalconditionthatcancausearangeofsymptoms,includingshortnessofbreath,chestpain,andcoughing.TraditionalChinesemedicinehaslongbeenusedtotreatavarietyofconditions,includingcancer,andrecentresearchhassuggestedthatTCMformulationsmaybeeffectivefortreatingmalignantpleuraleffusion.

ZhenWuTangJiaWeiisaTCMformulationthathasbeenusedforcenturiestotreatavarietyofconditionsrelatedtoyangdeficiencyandbloodstasissyndrome.ThisstudyaimedtoinvestigatewhetherZhenWuTangJiaWeicouldbeeffectivefortreatingmalignantpleuraleffusioninpatientswithyangdeficiencyandbloodstasissyndrome.

Thestudyinvolved48patientswithmalignantpleuraleffusionwhowererandomlyassignedtoeitheratreatmentgrouporacontrolgroup.ThetreatmentgroupreceivedZhenWuTangJiaWeitwiceadayforsixweeks,whilethecontrolgroupreceivedaplacebotwiceadayforsixweeks.

Theresultsofthestudyshowedthatthetreatmentgrouphadasignificantlyhigherrateofcompleteresponse(definedasthedisappearanceofpleuraleffusionforatleast4weeks)comparedtothecontrolgroup.Inaddition,thetreatmentgrouphadasignificantlyhigherrateofpartialresponse(definedasa>50%reductioninpleuraleffusion)comparedtothecontrolgroup.

ThestudyalsofoundthatZhenWuTangJiaWeiwaswell-toleratedbypatients,withnoseriousadverseeventsreported.

ThesefindingsareconsistentwithpreviousresearchsuggestingthatTCMformulationsmaybeeffectivefortreatingmalignantpleuraleffusion.However,furtherresearchisneededtoconfirmthesefindingsandtodeterminetheoptimaldosageanddurationoftreatment.

Inconclusion,thisstudyaddstothegrowingbodyofevidencesupportingtheefficacyandsafetyoftraditionalChinesemedicineformulationsforthetreatmentofmalignantpleuraleffusion.Whilemoreresearchisneeded,ZhenWuTangJiaWeimaybeaneffectiveandsafetreatmentoptionforpatientswithmalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndromeItisimportanttonotethattraditionalChinesemedicineshouldnotbeusedasasubstituteforconventionalcancertreatment,suchaschemotherapyandradiationtherapy.Instead,itshouldbeusedasacomplementarytherapytohelpmanagesymptomsandimproveoverallqualityoflifeforcancerpatients.

Furthermore,itiscrucialthattraditionalChinesemedicinepractitionersworkcloselywithoncologistsandothermedicalprofessionalstoensurethatthetreatmentplanissafeandeffectiveforeachindividualpatient.Thisincludesmonitoringforpotentialsideeffectsandinteractionswithothermedications.

MoreresearchisalsoneededtodeterminetheunderlyingmechanismsofZhenWuTangJiaWeiandothertraditionalChinesemedicineformulationsforthetreatmentofmalignantpleuraleffusion.Thiscouldhelptoshedlightonthepotentialbenefitsandlimitationsofthesetreatmentsandinformthedevelopmentofnewtherapiesandtreatmentstrategies.

Overall,traditionalChinesemedicineisapromisingandincreasinglypopularapproachtocancercarethatdeservesfurtherexplorationandintegrationwithconventionalmedicalpractices.WithcarefulconsiderationandcollaborationbetweentraditionalChinesemedicinepractitionersandmedicalpr